We recently reported that NSCLC p53 wild type cell lines were more sensitive to volasertib monotherapy, suggesting, in line with other studies, that p53 might be a predictive biomarker for Plk1 inhibition in NSCLC [21,23,24]. The gene discussed is PLK1; the disease is non-small cell lung carcinoma.